Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27,795,576
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
23,891,706
-
Shares change
-
+304,199
-
Total reported value, excl. options
-
$124,684,979
-
Value change
-
+$1,055,814
-
Put/Call ratio
-
16.02%
-
Number of buys
-
51
-
Number of sells
-
-36
-
Price
-
$5.22
Significant Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q4 2021
118 filings reported holding AXDX - Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share as of Q4 2021.
Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23,891,706 shares
of 27,795,576 outstanding shares and own 85.96% of the company stock.
Largest 10 shareholders include ORACLE INVESTMENT MANAGEMENT INC (3,627,549 shares), BlackRock Inc. (2,355,162 shares), Birchview Capital, LP (2,252,388 shares), VANGUARD GROUP INC (1,798,772 shares), Baird Financial Group, Inc. (1,508,069 shares), AXA S.A. (1,346,019 shares), STATE STREET CORP (1,093,823 shares), Cannell & Co. (1,086,919 shares), GRIFFIN ASSET MANAGEMENT, INC. (1,008,341 shares), and BLAIR WILLIAM & CO/IL (674,300 shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.